Asymmetric dimethylarginine downregulates sarco/endoplasmic reticulum calcium-ATPase 3 and induces endoplasmic reticulum stress in human umbilical vein endothelial cells

WEIKANG GUO, ZONGLI DIAO and WENHU LIU
Department of Nephrology, Beijing Friendship Hospital, Faculty of Kidney Diseases, Capital Medical University, Beijing 100050, P.R. China

Received January 17, 2017; Accepted September 6, 2017

DOI: 10.3892/mmr.2017.7529

Abstract. Cardiovascular disease is the leading cause of mortality in patients with chronic kidney disease. Endothelial cell injury and apoptosis may promote atherosclerosis and cardiovascular disease. The present study investigated the potential mechanisms of asymmetric dimethylarginine (ADMA)-induced apoptosis in human umbilical vein endothelial cells (HUVECs). It was demonstrated that ADMA decreased B-cell lymphoma-2 expression and increased cleaved-caspase-3 expression. Furthermore, terminal deoxyribonucleotidyl transferase (TdT)-mediated-digoxigenin-11-dUTP nick end labeling results indicated that ADMA induced apoptosis in HUVECs. These results suggest a potential mechanism of ADMA-induced endothelial cell injury. It was also verified that ADMA induced the expression of phosphorylated protein kinase RNA-like ER kinase, inositol requiring enzyme-1, C/EBP homologous protein and glucose-regulated protein, indicating activation of the endoplasmic reticulum (ER) stress response. Impaired function of sarco/endoplasmic reticulum calcium-ATPase (SERCA) is considered a major contributor to ER stress. It was demonstrated that ADMA induced a significant downregulation of SERCA3, however not SERCA2b. Overall, the results indicated that ADMA induced apoptosis in HUVECs, and that this effect was closely associated with induction of ER stress and decreased SERCA3 expression.

Introduction

The risk of death by cardiovascular disease (CVD) is greatly increased in chronic kidney disease (CKD). Besides the traditional risk factors, uremic toxins may be directly responsible for the pathogenesis of CVD in CKD. Asymmetric dimethylarginine (ADMA) is one of the most important uremic toxins that promote the progression of CKD (1). There is evidence of a strong association among atherosclerosis risk factors and ADMA levels (2-6). In previous reports, ADMA induced endothelial cell apoptosis (7,8), but the molecular biological mechanisms are not clear, yet. Endothelial cell injury and apoptosis can increase vascular permeability and enhance platelet activation and aggregation, thus promoting atherosclerosis and CVD.

Several recent studies proposed a role for endoplasmic reticulum (ER) stress in endothelial cell apoptosis and atherosclerosis. The ER facilitates protein folding and secretion. Impairment of normal ER function leads to an imbalance in protein homeostasis, accompanied by accumulation of misfolded proteins in the ER lumen, a condition referred to as ER stress. Activation of ER stress can ultimately return the ER to its normal physiological state. Three pathways activated during ER stress have been identified so far: Protein kinase RNA-like ER kinase (PERK), inositol requiring enzyme-1 (IRE1) and activating transcription factor 6 (ATF6). After activation of ER stress, improperly folded proteins undergo degradation, leading to expression of target genes including the ER chaperone, 78-kDa glucose-regulated protein (GRP78/BiP), and factors involved in degradation of unfolded proteins. The hypothesized purpose of ER stress is to promote cell survival by restoring ER function. However, prolonged activation of ER stress, an indication that the ER stress cannot be mitigated and homeostasis cannot be reestablished, correlates with cell death. Recently, PERK and IRE1 have been identified as factors involved in cell death (9,10).

The ER stress pathway can be evoked by abnormalities in calcium homeostasis. Calcium actively accumulates by sarco/endoplasmic reticulum calcium-ATPases (SERCAs) in the ER (11,12). Because the SERCA-dependent calcium transport is the only calcium uptake system in this organelle, regulation of SERCA function by the cell constitutes a key regulatory mechanism of calcium homeostasis in the ER. Impaired SERCA function is regarded as a major contributor to ER stress (13,14). The SERCA pump is encoded by a family of three genes, SERCA1, 2 and 3, which are highly conserved and located on different chromosomes (15). Expression of SERCA isoforms is cell-specific and developmentally regulated.

Correspondence to: Dr Wenhu Liu, Department of Nephrology, Beijing Friendship Hospital, Faculty of Kidney Diseases, Capital Medical University, 95 Yong An Road, Beijing 100050, P.R. China
E-mail: liuwh0211@126.com

Key words: ADMA, ER stress, apoptosis, SERCA
SERCA3 has been consistently shown to be co-expressed with SERCA2b in differentiated human umbilical vein endothelial cells (HUVECs) (16,17). In this study, we investigated whether ER stress is involved in ADMA-induced HUVEC apoptosis. We also explored whether the SERCA pathway is responsible for the ADMA-induced ER stress.

Materials and methods

Chemical reagents. ADMA was from Sigma-Aldrich (St. Louis, MO, USA). GRP78/BiP, IRE1 and cleaved caspase-3 antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). Bcl2, p-PERK, GAPDH and β-actin antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). SERCA2b and SERCA3 antibodies were purchased from Abcam Inc. (Cambridge, MA, USA). All other reagents, unless specially stated, were purchased from Sigma-Aldrich.

Cell culture. Primary HUVECs were from ScienCell Research Laboratories Inc. (Carlsbad, CA, USA). HUVECs were cultured in fibronectin-coated flasks using endothelial cell medium (ECM, ScienCell Inc.) with bullet kit additives (ScienCell Inc.) and 10% (v/v) fetal bovine serum (ScienCell Inc.). HUVECs used in the experiments were at passages 3-4.

Western blot analysis. Total protein was extracted from HUVECs with lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS and 1% PMSF). Protein concentration was determined using a BCA protein assay kit (Thermo Fisher Scientific, Waltham, MA, USA). Total protein each) were resolved on an 8 ‑12% SDS-PAGE gel and then to Kodak X-OMAT film (Eastman Kodak Inc.). HUVECs used in the experiments were at passages 3-4.

Results

ADMA treatment of HUVECs induces apoptosis. TUNEL staining was used to confirm apoptosis. As shown by TUNEL analysis (Fig. 1), HUVECs treated with 100 µM ADMA had a higher proportion of apoptotic cells than the control HUVECs. Bcl2, an apoptosis inhibitor, is a central modulator of intrinsic apoptosis. In HUVECs incubated with 100 µM ADMA for 48 h, Bcl2 was significantly downregulated (Fig. 2A and B). When HUVECs were incubated with various concentrations of ADMA (0-200 µM) for 24 h, the Bcl2 levels decreased in a dose-dependent manner (Fig. 2C and D). Furthermore, we analyzed the expression of cleaved caspase-3, a critical executioner of apoptosis. We found that ADMA increased cleaved caspase-3 expression in a time- and dose-dependent manner (Fig. 2E and F).

ER stress is involved in ADMA-induced HUVEC apoptosis. The ER stress pathway plays a role in apoptosis induction.
Therefore, we investigated whether the ER stress pathway is involved in the ADMA-induced apoptosis in HUVECs. The levels of the ER stress-related protein, GPR78/BiP, and the apoptosis-related ER stress proteins, PERK and IRE1 (9,10), were analysed by western blot. As PERK activation requires phosphorylation, we examined the level of phosphorylated PERK (p-PERK). As expected, ADMA induced PERK phosphorylation, and increased GPR78/BiP and IRE1 expression in HUVECs in a time-dependent manner (Fig. 3A and B). Moreover, ADMA induced p-PERK, GPR78/BiP and IRE1 expression in a dose-dependent manner (Fig. 3C and D). These results indicated that ER stress was involved in ADMA-induced HUVEC apoptosis.

**ADMA suppresses SERCA3 expression in HUVECs.** A recent study supported an important role for ER calcium homeostasis in the development of apoptosis. Because SERCA is the only calcium pump in the ER, we further hypothesized that its inhibition may evoke ER stress. Thus, we tested whether SERCA is modulated by ADMA by measuring the Ca\(^{2+}\)-ATPase activity. The results showed that ADMA (50-100 µM) significantly inhibited SERCA activity in HUVECs (Fig. 4A). Endothelial cells express two distinct isoforms, SERCA2b and SERCA3. It has been reported that in freshly isolated and early passage (P0-P1) HUVECs, SERCA3 was the dominant isoform. After further cell proliferation (P2-P4), there was a reduction in the expression of the SERCA3 isoform in HUVECs and a corresponding increase in SERCA2b (18). Therefore, we measured the levels of both HUVEC-associated SERCA isoforms by western blotting. We found that ADMA induced a slight, but not significant, decrease in SERCA2b protein expression (Fig. 4B-E). In contrast, ADMA induced a statistically significant downregulation of SERCA3 (Fig. 4F and G). This may be the mechanism of ADMA-induced ER stress and apoptosis in HUVECs. A decrease in SERCA expression leads to depletion of ER Ca\(^{2+}\) and increased cytosolic Ca\(^{2+}\) levels ([Ca\(^{2+}\)\(_{cyt}\)]. We therefore examined the [Ca\(^{2+}\)\(_{cyt}\)] levels in HUVECs. The change in the [Ca\(^{2+}\)\(_{cyt}\)] level was measured by confocal imaging using Fluo-3 dye in the presence of extracellular Ca\(^{2+}\). The change in fluorescence intensity after ADMA treatment was recorded, indicating the level of extracellular Ca\(^{2+}\). Fluorescence intensity measurements were made in every 3 sec. We found that ADMA treatment led to increased fluorescence intensity, which means that [Ca\(^{2+}\)\(_{cyt}\)] increased (Fig. 4H). Coloured lines represent every single cells. This may be the mechanism of ADMA-induced ER stress and apoptosis in HUVECs.

**Discussion**

CVD is the leading cause of death among CKD patients. There is an urgent need to characterize novel pathways and identify new therapeutic targets to control CVD progression.
Figure 2. ADMA suppresses Bcl2 and increased cleaved caspase-3 expression in HUVECs. (A-D) Cells were treated with the indicated concentration of ADMA (0-200 µM) for 24 h, or incubated with 100 µM ADMA for the indicated time periods. Bcl2 protein levels in cell extracts were analyzed by western blotting. Results are the mean ± SD (n=3). *P<0.05 compared with control. (E and F) Cells were treated with ADMA at the indicated dose (0-200 µM) and time period (0-48 h). Cell extracts were subjected to western blotting using antibodies against cleaved caspase-3.

Figure 3. ADMA induces ER stress-associated cell death in HUVECs. Cells were incubated with 100 µM ADMA for the indicated time periods (A) or with the indicated ADMA concentration (0-200 µM) for 24 h (B). GRP78/Bip expression was analyzed by immunoblotting. (C) Cells were incubated with 100 µM ADMA for the indicated time periods. The protein levels of phosphorylated PERK and IRE1 were examined by immunoblotting. Actin was used as a loading control. (D) After preincubation with various ADMA concentrations (0-200 µM) for 24 h, proteins were extracted and analyzed for p-PERK and IRE1 by western blotting. Results are the mean ± SD (n=3). *P<0.05 compared with control.
ADMA is a significant uremic toxin and its levels are elevated in CKD, even at the early stages. In a large cohort of subjects, those with higher ADMA levels had an increased risk of death attributed to cardiovascular disorders (19). Consistently, circulating ADMA levels have been shown to be independently associated with cardiovascular risk, death and incidence of CVD outcomes (5,6,20,21).

As an endogenous inhibitor of nitric oxide (NO) synthase, ADMA can reduce NO production. NO is a key factor maintaining vascular homeostasis. By reducing NO generation, ADMA can influence endothelial dysfunction (1). However, ADMA acts through mechanisms beyond its NO synthase inhibition. In previous reports, ADMA induced endothelial cell apoptosis (7,8). In our study, we also found that ADMA induced cleaved caspase-3 expression and decreased Bcl2 expression. These results demonstrated that endothelial cell apoptosis may contribute to ADMA-induced vascular injury.

ER stress results from the accumulation of misfolded proteins in the ER lumen. The likely purpose of ER stress is to help remove misfolded proteins and promote cell survival. However, prolonged ER stress triggers apoptosis. Among the three known ER stress sensors, PERK and IRE1 can trigger the cellular apoptosis program. Under normal conditions, BiP/GRP78 associates with and inactivates ER stress sensor proteins. Under stress conditions, GRP78/BiP dissociates from the ER sensor proteins, activating downstream signal transduction to rescue ER homeostasis. Increased GRP78/BiP levels in the ER compartment have been regarded as evidence for induction of ER stress. Several studies have strongly supported a central role for the ER stress response in the pathogenesis of endothelial dysfunction and CVD. Alleviating ER stress may thus represent a promising therapeutic approach for preventing or improving CVD. These studies led us to investigate whether ADMA induces ER stress in HUVECs. We confirmed that

ADMA treatment leads to increased cytosolic concentrations of free Ca$^{2+}$ through suppression of SERCA3. (A) HUVECs were stimulated with 0-100 µM ADMA for 24 h and SERCA activity in cell extracts was analyzed. (B-G) HUVECs were incubated with 100 µM ADMA for the indicated time periods or with various ADMA concentrations (0-200 µM) for 24 h. SERCA2 (B-E) and SERCA3 (F and G) levels were determined by immunoblotting. Results are the mean ± SD (n=3). *P<0.05 compared with control. (H) HUVECs were preloaded with Fluo-3 AM, and then stimulated with 75 µM ADMA. Serial Ca$^{2+}$ images of Fluo-3 fluorescence were recorded at the indicated times (sec).
ADMA induced p-PERK, IRE1 and GRP78/BiP expression in a time- and dose-dependent manner, indicating activation of the ER stress response. We further explored the possible mechanisms involved in ADMA-induced ER stress.

High concentrations of Ca\(^{2+}\) in the ER lumen ([Ca\(^{2+}\)\(_{\text{ER}}\)]) are essential for normal ER folding capacity (13). SERCA, localized in the ER membrane, lowers [Ca\(^{2+}\)\(_{\text{ER}}\)] by pumping Ca\(^{2+}\) from the cytosol into the ER. Inhibition of SERCA activity impaired ER Ca\(^{2+}\) homeostasis and caused prolonged ER stress (13,14). We therefore hypothesized that a disturbance in SERCA activity is the major cause of ADMA-induced ER stress in HUVECs. We found that ADMA inhibited the SERCA activity in HUVECs. The SERCA pump is coded by a family of three genes, SERCA1, 2 and 3, encoding the SERCA1, SERCA2 and SERCA3 isoforms, respectively. SERCA isoform expression is specific to cell type and developmental stages (15). While SERCA2b is a ubiquitous isoform expressed in muscle and non-muscle cells, the SERCA3 isoform is primarily expressed in non-muscle, especially endothelial, cells (16,17). Freshly isolated HUVECs contain only SERCA3 and no SERCA2b mRNA. These SERCA expression patterns change with increased cell proliferation. SERCA3 mRNA decreased, while that for SERCA2b increased, with increasing passages in culture. Because we used HUVECs at passages 3 and 4, we examined both SERCA2b and SERCA3 protein expression after ADMA stimulation. We found that ADMA slightly decreased SERCA2b expression, but more significantly reduced SERCA3 expression. This indicated that the ADMA-induced effects on SERCA were isoform-dependent. We also examined the changes in [Ca\(^{2+}\)\(_{\text{ER}}\)] in HUVECs in response to ADMA. We used Fluo-3 to detect the calcium levels in the cytoplasm. We found that the fluorescence intensity greatly increased after addition of ADMA to the culture medium. This result indicated that the [Ca\(^{2+}\)\(_{\text{ER}}\)] levels increased in HUVECs after ADMA stimulation.

Our results are consistent with other studies reporting that ADMA induced the ER stress response in many different cell types, such as mesangial cells, adipocytes, macrophages, glomerular endothelial cells and lung epithelial cells (22-27). These results implicated ER stress as the common pathway through which ADMA contributes to a variety of human diseases, including CKD, diabetes mellitus and liver disease. Thus, inhibition of ER stress and related pathways may be effective as a wide range treatment. However, there are a few limitations in our study. First, the SERCA isoforms expressed in HUVECs are influenced by the number of passages. Additionally, after 5 or 6 passages the cell phenotype changes to another phenotype, such as fibroblasts. Therefore, in this study we used cells from passages 3 and 4, which may be the main reason behind the finding that ADMA only obviously inhibited SERCA3, as it is the main isoform in the these passages. Hence, this in vivo experiment is limited by the cell culture. Thus, further in vivo experiments are required, to elucidate which isoforms are the main ones responsible for ADMA-induced ER stress in vascular cells. Moreover, in the normal population, the plasma level of ADMA is 0.92-0.11 µM (28,29). However, the plasma levels of ADMA are increased in some diseases, such as CKD, diabetes, cardiovascular disease and hypertension (30-32). Hemodialysis patients with atherosclerosis show significantly higher ADMA levels of up to 7.31 µM (33). However, when we performed experiments to study the toxicity mechanisms of ADMA in vitro, much larger doses (0-200 µM) than the pathological concentrations in clinical patients were required (22,25,34). Therefore, whether ADMA inhibits SERCA3 expression and induces ER stress during long-term ADMA accumulation in the human body still need to be explored in future in vivo studies.

In conclusion, we think that ADMA-induced ER stress and apoptosis are closely related to the decrease in SERCA3 expression.

In this study, we found that ADMA induced ER stress, decreased Bcl2 expression and ultimately induced apoptosis in HUVECs. In addition, ADMA decreased SERCA3 activity and expression. Together, our results indicated that ADMA induced growth suppression and apoptosis in HUVECs, effects that are related to activation of ER stress and inhibition of SERCA3 expression. Developing therapies that directly target the defective endogenous SERCA enzyme to correct Ca\(^{2+}\) imbalances in the ER may constitute a novel approach for treating ADMA-induced vascular injury.

Acknowledgements

The authors would like to thank the BeiJing Talents Fund (no. 2016000021469G223) for financial support.

References

1. Vallance P, Leone A, Calver A, Collier J and Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575, 1992.
2. Konya H, Miuchi M, Satani K, Matsutani S, Yano Y, Tsunoda T, Ikawa T, Matsuo T, Ochi F, Kusunoki Y, et al: Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus. World J Exp Med 5: 110-119, 2015.
3. Böger RH, Maas R, Schulze F and Schwedhelm E: Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 60: 481-487, 2009.
4. Landim MB, Casella Filho A and Chagas AC: Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: Implications for atherogenesis. Clinics 64: 471-478, 2009.
5. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, et al: Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: Results from the AtheroGene Study. Circ Res 97: e53-e59, 2005.
6. Lu TM, Ding YA, Chiang MJ and Lin SJ: Asymmetrical dimethylarginine: A novel risk factor for coronary artery disease. Clin Cardiol 26: 458-464, 2003.
7. Li J, Zhang Z, Lv L, Qiao H, Chen X and Zou C: (-)-epigallocatechin gallate inhibits asymmetric dimethylarginine-induced injury in human brain microvascular endothelial cells. Neurochem Res 41: 1868-1876, 2016.
8. Ma J, Zhao S, Gao G, Chang H, Ma P and Jin B: propucol protects against asymmetric dimethylarginine-induced apoptosis in the cultured human brain microvascular endothelial cells. J Mol Neurosci 57: 546-553, 2015.
9. Walter P and Ron D: The unfolded protein response: From stress pathway to homeostatic regulation. Science 334: 1081-1086, 2011.
10. Woehlbier U and Hetz C: Modulating stress responses by the UPfusosome: a matter of life and death. Trends in Biochem Sci 36: 329-337, 2011.
11. Zarain-Herzberg A, Garcia-Rivas G and Estrada-Aviles R: Regulation of SERCA pumps expression in diabetes. Cell Calcium 56: 302-310, 2014.
12. Brini M, Cali T, Ottolini D and Carafoli E: The plasma membrane calcium pump in health and disease. FEBS J 280: 5385-5397, 2013.
13. Fu S, Yang L, Li P, Hofmann O, Dicker L, Hide W, Lin X, Watkins SM, Ivanov AR and Hotamisligil GS: Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature 473: 528-531, 2011.
14. Li W, Ouyang Z, Zhang Q, Wang L, Shen Y, Wu X, Gu Y, Shu Y, Yu B, Wu X, et al: SBF-1 exerts strong anticervical cancer effect through inducing endoplasmic reticulum stress-associated cell death via targeting sarco/endoplasmic reticulum Cal(2+)-ATPase 2. Cell Death Dis 5: e581, 2014.
15. Periasamy M and Kalyanasundaram A: SERCA pump isoforms: Their role in calcium transport and disease. Muscle Nerve 35: 430-442, 2007.
16. Lipskaia L, Keuylian Z, Birlando K, Mougenot N, Jacquet A, Rouxel C, Sghairi H, Elaib Z, Blaise R, Adnot S, et al: Expression of sarco (endo)plasmic reticulum calcium ATPase (SERCA) system in normal mouse cardiovascular tissues, heart failure and atherosclerosis. Biochim Biophys Acta 1843: 2705-2718, 2014.
17. Mountian I, Manolopoulos VG, De SH, Parys JB, Missiaen L and Wuytack F: Expression patterns of sarco/endoplasmic reticulum Ca(2+)-ATPase and inositol 1,4,5-trisphosphate receptor isoforms in vascular endothelial cells. Cell Calcium 25: 371-380, 1999.
18. Anger M, Samuel JL, Marotte F, Wuytack F, Rappaport L and Lompré AM: In situ mRNA distribution of sarco (endo)plasmic reticulum Ca(2+)-ATPase isoforms during ontogeny in the rat: J Mol Cell Cardiol 26: 539-550, 1994.
19. Valkonen VP, Pärvi H, Salonen JT, Lakka TA, Lehtimäki T, Valkonen VP, Pärvi H, Salonen JT, Lakka TA, Lehtimäki T, J Mol Cell Cardiol 25: 539-550, 1994.
20. Nicholas SJ, Wang Z, Koehle R, Levison B, Dell’Amore B, Dzavik V, Griffith OW, Hathaway D, Panza JA, Nissen SE, et al: Metabolic profiling of arginine and nitric oxide pathways predicts hemodynamic abnormalities and mortality in patients with cardiac shock after acute myocardial infarction. Circulation 116: 2315-2324, 2007.
21. Tousoulis D, Bouras G, Antoniades C, Marinou K, Papageorgiou N, Miliou A, Hatzis G, Stefanadi E, Tsouflis C and Stefanadis C: Methionine-induced homocysteine impairs endothelial function in hypertensives: The role of asymmetrical dimethylarginine and antioxidant vitamins. Am J Hypertens 24: 1089-1099, 2011.
22. Park MJ, Oh KS, Nho JH, Kim GY and Kim DF: Asymmetric dimethylarginine (ADMA) treatment induces apoptosis in cultured rat mesangial cells via endoplasmic reticulum stress activation. Cell Biol Int 40: 662-670, 2016.
23. Hong D, Gao HC, Wang X, Li LF, Li CC, Luo Y, Wang KK, Bai YP and Zhang GG: Asymmetric dimethylarginine triggers macrophage apoptosis via the endoplasmic reticulum stress triggers. Mol Cell Biochem 398: 31-38, 2015.
24. Leng YP, Qiu N, Fang WJ, Zhang M, He ZM and Xiong Y: Involvement of increased endogenous asymmetric dimethylarginine in the hepatic endoplasmic reticulum stress of type 2 diabetic rats. PLoS One 9: e97125, 2014.
25. Guo W, Ding J, Zhang A, Dai W, Liu S, Diao Z, Wang L, Han X and Liu W: The inhibitory effect of quercetin on asymmetric dimethylarginine-induced apoptosis is mediated by the endoplasmic reticulum stress pathway in glomerular endothelial cells. Int J Mol Sci 15: 484-503, 2014.
26. Zhou QG, Zhou M, Hou FF and Peng X: Asymmetrical dimethylarginine triggers lipolysis and inflammatory response via induction of endoplasmic reticulum stress in cultured adipocytes. Am J Physiol Endocrinol Metab 296: E869-E878, 2009.
27. Lim SK, Choi H, Park MJ, Kim DL, Kim JC, Kim GY, Jeong SY, Rodionov RN, Han HJ, Yoon KC and Park SH: The ER-stress-mediated decrease in DDAH1 expression is involved in formaldehyde-induced apoptosis in lung epithelial cells. Food Chem Toxicol 62: 763-769, 2013.
28. Lundman P, Eriksson MJ, Stühlinger M, Cooke JP, Hamsten A and Tornvall P: Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 38: 111-116, 2001.
29. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, Kruzelnicka-Kwiatkowska O, Kokot F, Dubiel JS and Froelich JC: Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33: 652-658, 1999.
30. Alpoin MN, Sousa LP, Mota AP, Rios DR and Dusse LM: Asymmetric dimethylarginine (ADMA) in cardiovascular and renal disease: Clin Chim Acta 440: 36-39, 2015.
31. Tousoulis D, Georgakis MK, Oikonomou E, Papageorgiou N, Zaromidioti M, Latsios G, Papaoannou S and Siasos G: Asymmetric dimethylarginine: Clinical significance and novel therapeutic approaches. Curr Med Chem 22: 2871-2901, 2015.
32. Santilli F, Liani R, Di Pulvito P, Formosono G, Simeone P, Tripaldi R, Ueland T, Aukrust P and Davi G: Increased circulating resistin is associated with insulin resistance, oxidative stress and platelet activation in type 2 diabetes mellitus. Thromb Haematol 116: 1089-1099, 2016.
33. Kielstein JT, Böger RH, Bode-Böger SM, Schäffer J, Barbey M, Koch KM and Fröhlich JC: Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10: 594-600, 1999.
34. Wang LY, Zhang DL, Zheng JF, Zhang Y, Zhang QD and Liu WH: Apelin-13 passes through the ADMA-damaged endothelial barrier and acts on vascular smooth muscle cells. Peptides 32: 2436-2443, 2011.